and good everyone. operator, afternoon, Thanks,
commercializing Electrode. During the product our fiscal quarter, continued fourth towards second Evo our line, we sEEG to strides diagnostic exciting make
addition, substantial made we our financial therapeutic progress as our increased with we In well. runway technology, and development
our Let's efforts commercialization first product regarding sEEG the progress discuss Evo line. with
in from for We line, less clearance in FDA the Cortical expect Evo as and received for commercial days now product Zimmer to than use similar the with Biomet our begin indications the October launch XX XXXX first quarter of to procedures neurosurgeons. placement. electrode bulk less represent of Electrodes due a by procedures today Many enhance XXXX. invasive placement these currently precision during the their of performed utilize diagnostic to sEEG robot
future shipped ramping launch. ROSA We full Electrodes a up recently be Evo in initial meet platform robotic additional Zimmer's Biomet same limited expect and the to sEEG orders The market with manufacturing Zimmer is Evo also the the used release product sEEG manner. company to for to order
calendar completion fourth animal that XXXX. system, the with electrode potential calendar feasibility development to end we ablation studies therapeutic were had we OneRF of the the our previously by to product the year complete quarter, in reported of targeting Moving
reminder, ablate being tissue record the and system designed same brain activity a the is both brain to using electrode. As
to treat one patient diagnostic device into cost due seizures one patients the hospital to required is therapeutic, surgeries, that both one improve functions epilepsy. time, for separate to are and visits therapeutic for to outcomes. Combining have potentially intended two and Currently, and diagnostic contribute and save
also system offer customers. to intent our the generator complete our a have market electrode and to to radiofrequency We discussed both
also we agreement recognized and develop our Innovations, and leader signed that generator. previously to I RBC devices, manufacturing radiofrequency disclosed Medical partnership the electromechanical with a in therapeutic a of development manufacture
on We completed have hardware the now preliminary and prototypes tests design software the for verification generator.
Van Atlanta, also studies Dr. assistance Dr. and animal Jamie successfully the Mayo Gross Clinic Rochester, in Georgia; feasibility the with Gompel of University Emory Robert completed at in We of Minnesota.
discuss let's can in for used our Now efforts recording. chronic electrodes that stimulation and developing be
back for make failed on disorder, pain therapeutic depression, these peripheral epilepsy, Parkinson's diagnostic due functions. continue both that pain, electrodes in and to deliver progress potentially indications as being obsessive mental health as are and use conditions We indications such permanently electrode testing and implanted that can back requiring to a of the disease, designed severe such surgeries, other compulsive
of billion is $X market, currently in U.S. the revenue focus stimulation initial cord represents target to spinal which Our the over market.
systems the of utilize placed expanded with current competitive tissue designing as are battery to less meaning percutaneous electrodes our devices require while energy delivery to that designs coverage placements, We compared targeting nonsurgical percutaneously.
development also delivery to of neurosurgeons comprised have device guide system. the specialists leaders help We key and and recruited pain both electrode of opinion both the in
American with also for the has quarters, focus the We of fourth our third Health to technology. the and Institute of company Society been Epilepsy of Surgeons, included invasive company potential presented both electrodes. of less procedure Medtronic Neurological The through In conferences. required sensing place built would to fiscal for part Minnesota of one that would Neuroscience, University Medtronic National generate plugged market generator the to area Another electrode could into at intent a pre directly were data to functionality a assistance and clinical be post submissions electrode into stimulation pulse is effort also the Society provide a the the cortical the support and as the typically from with and Congress place develop electrode. that that cortical to
the a our From as position providing amendment by from company's related having financial greater runway, distribution million This milestone $X.X without received and an to Biomet certain approach events an development standpoint, to markets. financial currently of we payment accelerated part Zimmer agreement. to strengthens the challenging financial
brief on financial of it for Ron? turn to Ron update I'll our the reporting. status over a now
